

Disclaimer and notes



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES OR TO "US PERSONS" (AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")) OR INTO OR WITHIN AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION (THE "MATERIALS") IN JURISDICTIONS OUTSIDE THE UK SHOULD INFORM THEMSELVES ABOUT AND OBSERVE ANY APPLICABLE LEGAL REQUIREMENTS IN THEIR JURISDICTIONS. IN PARTICULAR, THE DISTRIBUTION OF THE MATERIALS MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS. ACCORDINGLY, RECIPIENTS REPRESENT THAT THEY ARE ABLE TO RECEIVE THE MATERIALS WITHOUT CONTRAVENTION OF ANY APPLICABLE LEGAL OR REGULATORY RESTRICTIONS IN THE JURISDICTION IN WHICH THEY RESIDE OR CONDUCT BUSINESS.

The information presented herein is not an offer for sale within the United States of any equity shares or other securities of Apax Global Alpha Limited ("AGA"). AGA has not been and will not be registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition, AGA's shares (the "Shares") have not been and will not be registered under the Securities Act or any other applicable law of the United States. Consequently, the Shares may not be offered or sold or otherwise transferred within the United States, or to, or for the account or benefit of, US Persons, except pursuant to an exemption from the registration requirements of the Securities Act and under circumstances which will not require AGA to register under the Investment Company Act. No public offering of the Shares is being made in the United States.

This document represents the quarterly report of AGA. It does not constitute an advertisement and is not a prospectus. It does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein in the United States or in any other jurisdiction, nor shall it, by the fact of its distribution, form the basis if, or be relied upon, in connection with any such contract. No offer, invitation or inducement to acquire Shares or other securities in AGA is being made by, or in connection with, this document.

The information and opinions contained in this document are for background purposes only, do not purport to be full or complete and do not constitute investment advice. Subject to AGA's regulatory requirements and responsibilities, no reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness and no representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this document by AGA or any of its affiliates and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. This information is not intended to provide, and should not be relied upon for accounting, legal, tax advice or investment recommendations. You should consult your tax, legal, accounting or other professional advisors about the issues discussed herein. The descriptions contained herein are summaries and are not intended to be complete and neither AGA nor any of its affiliates undertakes undertakes undertakes undertakes undertakes undertakes undertakes undertakes undertakes any obligation to update or correct any errors or inaccuracies in any of the information presented herein. The information in this document and any other information discussed at the presentation is subject to change. This document does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase any investment nor shall it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract thereof.

The Materials may include forward-looking statements. The words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding AGA's intentions, beliefs or current expectations concerning, among other things, AGA's results of operations, financial condition, liquidity, prospects, growth and strategies. The forward-looking statements in the Materials are based on numerous assumptions regarding AGA's present and future business strategies and the environment in which AGA will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of AGA to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond AGA's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as AGA's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which AGA operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. AGA expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in AGA's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of the Materials, or to update or to keep current any


Note this presentation covers the period from 1 July 2017 to 30 September 2017 unless otherwise indicated.

The contents of this Presentation, which have been prepared by and are the sole responsibility of the Company, have been approved by Apax Partners LLP solely for the purposes of section 21(2)(b) of the Financial Services and Markets Act 2000, as amended (the "FSMA").

This Presentation is not intended to be marketing as defined in an EU jurisdiction under the EU's Alternative Investment Fund Managers Directive (2011/61/EU).

Date: 31 October 2017

Financial Highlights





Total NAV Return¹ 3017

-0.3%/2.0%³

Adjusted NAV² at 30 September 2017

€881.9m/£777.9m

Highlights

- Total NAV Return was negative 0.3%
- Financial quarter again impacted by adverse FX movements as the euro continued to strengthen against the US dollar. Adjusting for FX, Total NAV Return was positive 2.0%³

Adjusted NAV per share at 30 September 2017

€1.80/£1.58

Dividends per ordinary share paid in respect of 1H17 (€/£)

4.69c/4.24p

 Adjusted NAV per share of €1.80, down from €1.85 at 30 June 2017 with dividend payment and adverse FX movements offsetting investment gains

- Dividend of €23.0m paid in September 2017, in line with Company's policy of 5% annual dividend yield
- AGA was 99% invested at 30 September 2017
- AGA was included in the FTSE All-Share Index and FTSE Small-Cap Index on 18 September

Market capitalisation at 30 September 2017

€840.8m/£741.6m

Percentage of funds invested at 30 September 2017


99%

^{1.} Total NAV Return means the movement in the Adjusted NAV per share over the period plus any dividends paid. Adjusted NAV per share used in the calculation is rounded to 5 decimal points


^{2.} Adjusted NAV represents NAV of €881.9m adjusted for the estimated performance fee reserve of €13.6m at 30 September 2017


^{3.} FX adjusted

Adjusted NAV development and performance









Highlights

- Adjusted NAV decreased by €26.2m mainly due to a dividend payment of €23.0m and adverse FX effects of €20.5m
- Unrealised gains of €15.3m contributed positively with €11.1m from the PE portfolio
- Excluding FX, both Private Equity and Derived Investments contributed positively to performance
 - Private Equity contribution: 1.3%
 - Derived Investment contribution: 1.0%
- FX movement mainly driven by the euro appreciating 3.3%³ against the US dollar in 3Q17 with negative impact of 2.3% on Total NAV Return
- AGA does not employ a currency hedging strategy

^{1.} See slide 24 in the appendix for details regarding per share data


^{2.} Performance fee adjustment accounting for the movement in estimated performance fee reserve at 30 September 2017

^{3.} Source: Bloomberg

AGA invested portfolio at 30 September 2017







^{1.} Excludes cash and cash equivalents and net current assets, including these the NAV is €895.5m. Adjusted NAV excludes the estimated performance fee and is €881.9m at 30 September 2017



Private Equity activity in 3Q17




An active quarter with four new deals closed in Apax IX and two in AMI

Acquisitions					
Closed ¹		Cost ²	Announced ¹		Estimated cost ²
SYNERON CANDELA	Global non-surgical aesthetic device company (AIX, North America, Healthcare)	€12.0m	Thought Works [®]	Global software development and digital transformation consulting company (AIX, North America, Tech & Telco)	c.€15m
safety kleen	Largest provider of surface treatment and chemical application services (AIX, UK, Services)	€12.5m	MATCHES FASHION.COM	Leading luxury, multi-brand ecommerce retailer (AIX, Europe, Consumer)	c.€18m
אא א א א א א א א א א א א א א א א א א א	Israel's largest general discount retail chain (AMI, Israel, Consumer)	€2.6m			
■ Go global travel	Leading B2B travel technology and service provider (AMI, Israel, Tech & Telco)	€3.9m			,
MANAPPURAM FINANCE LIMITED Make Life Easy	One of India's leading gold loan NBFCs (AIX, India, Services)	€2.9m			
ECi Software Solutions	Provider of enterprise resource planning software solutions (AIX, North America, Tech & Telco)	€9.5m			

^{1.} Syneron Candela, Safetykleen and Max Stock closed in July 2017. Go Global Travel and Manappuram Finance closed in August 2017. ECi was announced in August 2017 and closed in September 2017. Thought Works and Matches Fashion were announced August 2017. Attenti which was announced in June 2017, closed in October 2017


^{2.} Cost and estimated cost are AGA's indirect exposure to the underlying portfolio companies held by the Apax Funds. Costs may change following final close of the deal or the completion of a syndication post closing

Private Equity Adjusted NAV development and performance









Highlights

- Total calls of €70.0m were paid in relation to Apax IX². AMI transactions were bridge financed and a call is expected in December 2017
- Distributions from divestments in Apax VIII of €8.6m and AMI of €0.3m
- Unrealised gains contributed €11.1m to performance, driven mainly by organic growth across the portfolio
- Largest absolute fair value gains in 3Q17 from:
 - Takko (+€2.8m, current NAV⁴: €3.1m)
 - Assured Partners (+€2.6m, current NAV⁴: €49.8m)
 - Azelis (+€2.5m, current NAV⁴: €49.2m)
- Biggest portfolio mark-downs during 3Q17:
 - Shriram City Union (-€4.6m, current NAV⁴: €14.7m)
 - Ideal Protein (-€2.1m, current NAV⁴: €10.8m)
 - One Call (-€2.1m, current NAV⁴: €15.3m)
- FX movement mainly due to the appreciation of the euro against the US dollar by 3.3%⁵
 - 43% of AGA's PE portfolio is denominated in US dollars

^{1.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 30 September 2017

^{2.} Calls of €70.0m were to fund AIX investments in ECI, Thought Works, Attenti, Matches Fashion and Tosca Services which was announced post Q3. Investments in Unilabs, Guotai, Kepro, Safetykleen, Syneron Candela and Manappuram were bridge financed and AGA is expected to pay another call in December 2017

^{3.} Includes AGA's exposure to carried interest holdings in Apax Europe VII which was valued at €19.8m at 30 September 2017


^{4.} Current NAV represents AGA's gross indirect look-through NAV in the Apax Funds at 30 September 2017

^{5.} Source: Bloomberg

Private Equity valuation drivers



Total Return of negative 0.2% for the nine months to September



Highlights

- Growth in underlying earnings contributed 11.4% to Total Return in the last nine months from organic growth and through M&A activity
- Movements in net debt reduced Total Return by 7.0% predominantly reflecting the continued debt funded M&A activity of portfolio companies in Apax VIII and Apax IX
- Valuation multiples have increased, contributing 7.7% to Total Return as stock markets continue to rally across US and Europe

- FX reduced Total Return by 7.2% mainly due to the euro strengthening against the US dollar
- AGA's AEVII carried interest valuation remained relatively flat compared to December 2016
- Management fees and carried interest accruals reduced AGA return by 3.8% in the period


Together these three performance drivers represent a return of 12.1%

^{1.} Represents movement in all instruments senior to equity


^{2.} Movement in the valuation multiples captures movement in the comparable companies valuation multiples. In accordance with International Private Equity and Venture Capital Valuation ("IPEV") guidelines, the Apax Funds use a multiples based approach where an appropriate valuation multiple (based on both public and private market valuation comparators) is applied to maintainable earnings, which is often but not necessarily represented by EBITDA to calculate enterprise value


^{3.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 30 September 2017

Private Equity operating metrics












Highlights

- LTM EBITDA accelerated to 17.1% on average and LTM revenue to 11.8% driven largely due to the impact of M&A
- Valuation multiples at which the portfolio companies are held in the Apax Funds increased from 13.1x LTM EBITDA to 13.3x LTM EBITDA, reflecting an uplift in valuation multiples used to value the Private Equity portfolio
- The average leverage level of portfolio companies reduced to 4.3x LTM EBITDA mainly driven by EBITDA growth despite absolute net debt increasing







September 2017
 June 2017
 Number of investments within the associated band

Note: These operational metrics represent a snapshot of the portfolio as at period end, hence they do not capture the performance of exited investments in the reporting period

- 2. New closed investments in 3Q17 See slide 7 for full list of acquisitions. June 2017 represents new investments in the 3 months to 30 June 2017
- 3. There were no disposals in 3Q17. June 2017 represents full exits in the 3 months to 30 June 2017

^{1.} At June 17 and September 17 four and eight investments were respectively excluded as these are large positive outliers, financial services companies often valued on book value or for which clean earnings financials are not available e.g. complex carve-outs or recent acquisitions. The increase was due to new portfolio additions and one financial services company newly excluded. September 17 averages are unmoved when re-included: LTM Revenue growth of 11.9%, LTM EBITDA growth of 17.1%, Valuation multiple of 13.1x and Leverage of 4.2x



Derived Investments activity in 3Q17



Continued focus on Derived Equity with selective investments made in Derived Debt

Acquisition	ss ¹							
Debt		Cost ²	Equity		Cost ²	Equity (Add-on)		Cost ²
safety kleen	Europe's largest service provider of surface treatment and chemical application services (Europe, Services, 2 nd lien)	€11.0m	SINOPHAR ^M	Largest wholesaler and retailer of pharmaceutical products in China (China, Healthcare)	€12.6m	Tech Mahindra	IT services, outsourcing and consulting company (India, Tech & Telco)	€0.3m
pdc brands	One of the fastest growing beauty companies in the world (Europe, Consumer, 2 nd lien)	€8.5m	(KRKA	Slovenian generic pharmaceutical company focused on commodity and branded products (Europe, Healthcare)	€19.8m	Strides Shasun	An Indian pharmaceutical company (India, Healthcare)	€1.8m
RIEMSER ~	German based speciality pharmaceutical company (Europe, Healthcare, 1 st lien)	€18.2m	企业 VIPSHOP.COM 一家专门做特卖的网站	Largest independent online discount retailer in China (China, Consumer)	€12.7m			
<u>syncsort</u>	A global software company specializing in Big Data, high speed sorting products, and data integration software and services (North America, Tech & Telco, 2 nd lien)	€20.8m	EVRY	Nordic IT services and FinTech company (Europe, Tech & Telco)	€3.7m			
			⇒ talend	Open source SaaS provider of data management solutions (North America, Tech & Telco)	€6.6m			

^{1.} During 3Q17, AGA's investment in Rue21 first lien debt was restructured and in lieu of this AGA received Rue21 Equity. The Rue21 DIP facility (Debtor-in-Possession) AGA held was also converted into a new first lien term loan. These have been excluded from the above

^{2.} Represents the cost paid in the quarter

Derived Investments activity in 3Q17



IRR performance from exited investments was generally attractive

Divestments ¹							
Debt		Initial year of purchase	Gross IRR ²	Equity		Initial year of purchase	Gross IRR ²
AssuredPartners _{INC}	Leading mid-market property, casualty and employee benefits insurance brokerage (North America, Services)	2015	9%)		Chinese online job portal (China, Tech & Telco)	2016	16%
• azelis	Leading global distributor of specialty chemicals and related services (Rest of Europe, Services)	2016	13%)	 <epam></epam>	Specialised outsourced product development services provider (Rest of Europe, Tech & Telco)	2016	30%)
Answers™	An internet-based knowledge exchange (North America, Services)	2014 ³	-21%				

^{1.} Full exits. Excludes the Rue21 first lien debt that was restructured in September 2017


^{2.} Gross IRR calculated since the initial purchase date of the investment. For assets purchased prior to 15 June 2015, the IPO date, the gross IRR is calculated based on the initial purchase price in PCV


^{3.} AGA initially purchased debt in Answers first lien debt in November 2014. In April 2017, the first lien debt was restructured and AGA received equity and new second lien debt in lieu of the first lien notes held. The new second lien debt received in April 2017 was subsequently sold in September 2017 and the gross IRR represents the gross IRR on the disposal of the new second lien debt only

Derived Investments Adjusted NAV development and performance



Good underlying performance of the Derived Investment portfolio (setting aside FX)





Highlights

- Adjusted NAV increased by €43.6m to €350.7m in 3Q17, mainly driven by the 11 acquisitions completed in the quarter
- Total of €119.2m was invested. €58.9m into 4 new debt investments and €60.3m in to 7 equity positions
- Realisations of €68.0m consisted of €58.9m from 3
 Derived Debt realisations and €9.1m from 2 Derived
 Equity realisations
- Negative Total Return of 0.7% mainly driven by FX as the euro continued to strengthen against major currencies. 89% of AGA's Derived portfolio is held in currencies other than the euro
- Positive contribution of 3.6% to Total Return; with income of 2.2% and unrealised gains of 1.6%
- Income reflecting interest and dividends earned on the Derived Investments portfolio
- Largest absolute fair value gains and losses in 3Q17²:
 - Sophos (+€5.5m, current NAV: €29.3m)
 - Tech Mahindra (+€2.1m, current NAV: €14.5m)
 - Full Beauty (+€1.1m, current NAV: €15.4m)
 - Vipshop (-€3.1m, current NAV: €9.5m)
 - Strides Shasun Ltd (-€2.4m, current NAV: €15.1m)
 - Paradigm³ (-€1.7m, current NAV: €9.4m)

^{1.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 30 September 2017


^{2.} Absolute fair value gains calculated by taking the unrealised fair value movements, realised gains and income earned in the quarter


^{3.} At 30 September 2017, AGA marked Paradigm debt based on best available pricing information available at the time. Post quarter end, the Apax Funds announced the sale of Paradigm and the debt is expected to be repaid at par in 4Q17. This represents a mark-up of €7.3m compared to the fair value at 30 September 2017

Derived Investments Adjusted NAV development and performance



Derived Debt performance improving – Derived Equity flat but strong YTD





Derived Debt

- Derived Debt performance improved during Q3: Investment gains² of 2.3% vs 1.2% in H1
- FX movements were seen in the Derived Debt portfolio due to the large exposure (84%) to US dollar denominated debt
- Post quarter end, the Apax Funds announced the sale of Paradigm and the debt is expected to be repaid at par in 4Q17³. This will represent a markup of €7.3m compared to the fair value at 30 September 2017

Derived Equity

- Largest positive driver were unrealised gains driven by robust share price performance in 11 out of 16 listed equity positions with the greatest gains from Sophos and Tech Mahindra offset by losses in Vipshop and Strides
- Dividend income of €0.8m was earned from 5 equity positions contributing 0.2% to returns in the quarter
- FX continued to impact returns

^{1.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 30 September 2017


^{2.} Investment gains represent income, realised losses and unrealised losses


^{3.} The transaction remains subject to certain closing conditions


Derived Investments operating metrics


Debt yield to maturity 13.1%













Highlights

- Average LTM EBITDA growth decreased to 1.5% for Derived Debt investments mainly due to the exit of two portfolio companies with higher EBITDA growth (Assured and Azelis)
- Average LTM earnings growth increased to 8.7% for Derived Equity investments mainly due to the addition of higher growth portfolio companies (KRKA, Sinopharm, Vipshop) and disposal of lower growth companies (Zhaopin and Epam)
- Average yields to maturity have decreased marginally from 13.6% to 13.1% due to three old positions and four new positions changing the portfolio mix





September 2017June 2017

Number of investments within the associated band

Note: These operational metrics represent a snapshot of the portfolio as at period end, hence they do not capture the performance of exited investments in the reporting period

- 1. GAV weighted average of the respective metric across the Derived Investments Debt portfolio
- 2. GAV weighted average of the respective metric across the Derived Investments Equity portfolio. (Cengage, Talend, Answers & Rue21 have been excluded from the analysis above)
- 3. GAV weighted average of the current full year income (annual coupon/clean price as at the respective date) for each debt position in the Derived Debt portfolio as at the respective date
- New closed investments in the 3Q17 See slide 12 for full list of acquisitions (inclusive of add-on positions but excluding new positions received as part of restructuring of Rue21)
- 5. Represents full exits during 3Q17- See slide 13 for list of disposals

Conclusions and Outlook



3Q17 summary

- Total NAV Return was negative 0.3% due to adverse FX movements, positive 2.0% on a constant currency basis
- Private Equity portfolio with sound operational performance: LTM EBITDA growth of 17.1%. Average leverage of 4.3x
- Improving performance in Derived Debt adding 0.5% to Total NAV Return Derived Equity with a strong year to date performance of 19.9%
- First interim dividend of 4.24p in respect of 1H17 paid on 15 September, equivalent to 2.5% of NAV at 30 June 2017
- AGA became part of the FTSE All-Share and Small Cap Indices on 18 September widening the investor base

Private Equity outlook

- On a relative basis PE appears the most attractive asset class. While valuations
 are equally high as in public equities, active management of strategic and
 operational improvements can allow portfolio companies to mature into their
 high valuations
- Positive outlook on the Apax Funds:
 - Difficult assets have been worked through earlier in the year (eg Rue21, Paradigm, Answers)
 - Performing assets are increasing in size on both an absolute and relative basis
 - Improving performance in previously slowly growing assets (eg Quality Distribution, Takko, Azelis)
- AIX is exhibiting a high investment rate with its two-prong strategy:
 - "off the beaten track" value picks (eg Attenti)
 - Exceptionally high growth picks (eg MatchesFashion, Thoughtworks)

Derived Investments outlook

- Portfolio focus remains on listed equity investments which often provide more attractive risk / return trade-offs than debt at this point in time. Over the past nine months €125.7m has been invested in to Derived Equity, €110.8m in to Derived Debt
- In Derived Debt:
 - Loans remain more attractive than high yield notes
 - Continue to seek out opportunistic/idiosyncratic/value oriented assets which are under-rated by the market (eg Riemser)
- In Derived Equities focus on relative value and on the lookout for opportunities in emerging markets
 - IT services (eg Take, Tech Mahindra)
 - Online/digital (eg Vipshop, Talend)
 - Healthcare (eg KRKA)





The Company

Apax Global Alpha Limited



About AGA

AGA is a closed ended investment company that invests in a diversified portfolio of Private Equity Investments and Derived Investments in debt and equities. The Company was admitted to trading on the Main Market of the London Stock Exchange on 15 June 2015. On 18 September 2017, the Company became part of the FTSE All-Share and Small-Cap Indices

What AGA does

- > Set business objectives and investment strategy
- > Governance and risk management
- > Appointment and oversight of service providers

The Investment Manager

Apax Guernsey Managers Limited

About AGML

AGA has appointed Apax Guernsey Managers Limited ("AGML" or the "Investment Manager") as its discretionary Investment Manager. AGML is managed by a board of experienced investment professionals and operational private equity executives.

What AGML does

- > Discretionary portfolio management
- > Investment and divestment decisions
- > Portfolio performance analysis and risk management

The Investment Adviser

Apax Partners LLP



About Apax Partners

Apax Partners LLP is a leading global private equity advisory firm and acts as Investment Adviser to AGML. It operates globally and has more than 30 years of investing experience. Apax Partners has raised and advised funds that total over €42bn in aggregate at 30 September 2017.

What Apax Partners does

- > Identification and due diligence of investment opportunities
- > Recommendation of potential investments to AGML for consideration

The Investment Adviser

Apax Partners



Industry leader

Over €42 billion equivalent of funds raised to date

Pioneer in Private Equity

Established in 1969 in the US and 1972 in Europe¹

Significant global reach


8 offices in 7 countries

Deep bench of industry specialists


c.120 investment professionals

Industry focused investments

Tech & Telco Services
Healthcare Consumer









Top 30 Private Equity Investments at 30 September 2017

Private Equity Portfolio (look-through basis) – AGA's indirect exposure

		Fund	Geography	Sector	Valuation €m	% of NAV	% of invested portfolio
1.	Assured Partners*	AVIII	North America	Services	49.8	6%	6%
2.	Azelis	AVIII	Rest of Europe	Services	49.2	5%	6%
3.	EVRY*	AVIII	Rest of Europe	Tech & Telco	39.1	4%	4%
4.	Exact Software*	AVIII	Rest of Europe	Tech & Telco	37.8	4%	4%
5.	Engineering	AVIII	Rest of Europe	Tech & Telco	26.8	3%	3%
6.	Idealista	AVIII	Rest of Europe	Consumer	25.3	3%	3%
7.	Unilabs	AEVI & AIX	Rest of Europe	Healthcare	24.5	3%	3%
8.	GlobalLogic	AVIII	Rest of World	Tech & Telco	24.5	3%	3%
9.	Wehkamp	AVIII	Rest of Europe	Consumer	20.3	2%	2%
10.	NuPharm365	AVIII	Rest of Europe	Healthcare	20.0	2%	2%
11.	Duck Creek Technologies	AVIII	North America	Tech & Telco	15.7	2%	2%
12.	One Call	AEVII 8 AVIII	North America	Healthcare	15.3	2%	2%
13.	Acelity	AEVII	North America	Healthcare	14.8	2%	2%
14.	Vyaire Medical	AVIII	North America	Healthcare	14.8	2%	2%
15.	Shriram City Union	AVIII	India	Services	14.7	2%	2%
16.	Cole Haan*	AVIII	North America	Consumer	14.2	2%	2%
17.	Syneron Candela	AIX	North America	Healthcare	13.4	1%	2%

Private Equity Portfolio (look-through basis) – AGA's indirect exposure

		Fund	Geography	Sector	Valuation €m	% of NAV	% of invested portfolio
18.	Safetykleen*	AIX	UK	Services	12.8	1%	1%
	Quality						
19.	Distribution*	AVIII	North America	Services	12.3	1%	1%
20.	Ideal Protein	AVIII	North America	Healthcare	10.8	1%	1%
				Tech &			
21.	ECI	AIX	North America	Telco	9.5	1%	1%
22.	Psagot	AEVII	Rest of world	Services	8.8	1%	1%
	Guotai Junan						
23.	Securities	AIX	China	Services	8.4	1%	1%
		AEVI &		Tech &			
24.	Tivit	AEVII	Rest of world	Telco	7.2	1%	1%
25.	Boats Group	AIX	North America	Services	6.4	1%	1%
26.	Kepro	AIX	North America	Healthcare	6.3	1%	1%
27.	Full Beauty*	AVIII	North America	Consumer	6.0	1%	1%
	Zensar			Tech &			
28.	Technologies	AVIII	India	Telco	5.7	1%	1%
		AEVII &					
29.	Genex*	AVIII	North America	Healthcare	5.6	1%	1%
		AEVI &		Tech &			
30.	Sophos*	AEVII	UK	Telco	5.4	1%	1%
	Total Top 30 -	Gross va	lues		525.4	59%	60%
	······		ts, carried intere	st_facility &	J_J,-T	3370	00/0
	NCA's)	i v Cottilett	co, carrica intere	se, racincy &	(2.6)	(1%)	(1%)
	Total Top 30 -	Gross va	lues		522.8	58%	59%

^{*} Denotes overlap with the Derived Investments portfolio



Top 30 Derived Investments at 30 September 2017

	% of										
		Instrument	Geography	Sector	Valuation €m	% of NAV	invested portfolio				
				Tech &							
1.	Sophos*	Listed equity	UK	Telco	29.3	3%	3%				
			North	Tech &							
2.	Syncsort	2L term loan	America	Telco	21.0	2%	2%				
			Rest of								
3.	KRKA	Listed equity	Europe	Healthcare	19.4	2%	2%				
			North								
4.	Genex*	2L term loan	America	Healthcare	18.9	2%	2%				
			Rest of								
5.	Riemser	1L term loan	Europe	Healthcare	18.9	2%	2%				
			North	Tech &							
6.	Rentpath	2L term loan	America	Telco	18.2	2%	2%				
	Quality		North								
7.	Distribution*	2L term loan	America	Services	16.1	2%	2%				
			North								
8.	Full Beauty*	2L term loan	America	Consumer	15.4	2%	2%				
	Advantage										
	Sales &		North								
9.	Marketing	2L term loan	America	Consumer	15.2	2%	2%				
	Strides										
10.	Shasun	Listed equity	India	Healthcare	15.1	2%	2%				
	Tech			Tech &							
11.	Mahindra	Listed equity	India	Telco	14.5	2%	2%				
12.	Sinopharm	Listed equity	China	Healthcare	13.2	1%	1%				
	Exact		Rest of	Tech &							
13.	Software*	2L term loan	Europe	Telco	12.6	1%	1%				
	Palo Alto		North	Tech &							
	Networks	Listed equity	America	Telco	12.2	1%	1%				
15.	Safetykleen *	[°] 2L term loan	UK	Services	11.1	1%	1%				
	Development	t									

	Derived Investments Portfolio (ctd)												
		Instrument	Geograph	y Sector	Valuation €m	% of NAV	% of invested portfolio						
	China Cinda												
17.	Asset Mgmt	Listed equity	China	Services	9.7	1%	1%						
18.	Vipshop	Listed equity	China	Consumer	9.5	1%	1%						
				Tech &									
19.	Paradigm*	2L term loan	UK	Telco	9.4	1%	1%						
			North	Tech &									
20.	Vertafore	2L term loan	America	Telco	8.7	1%	1%						
			North										
21.	PDC Brands	2L term loan	America	Consumer	8.3	1%	1%						
	TAKE			Tech &									
22.	Solutions	Listed equity	India	Telco	8	1%	1%						
			North	Tech &									
23.	Talend	Listed equity	America	Telco	7.2	1%	1%						
			North	Tech &									
24.	Epicor	2L term loan	America	Telco	6.4	1%	1%						
2.5			North		6.2	40/	40/						
25.	Answers	Equity	America	Services	6.2	1%	1%						
	Shriram												
26	Transport Finance	Listed equity	India	Services	5.8	1%	1%						
20.	rmance	Listed equity Equity &	North	Services	5.8	170	170						
27	Rue21	1L term loan	America	Consumer	4.7	1%	1%						
۷,۰	Caliber	TE CEITH IOAH	North	CONSUME	7./	1/0	1/0						
28.		2L term loan	America	Consumer	4.3	0%	0%						
			Rest of	Tech &		0,0	0,0						
29.	EVRY*	Listed equity	Europe	Telco	4.1	0%	0%						
	Cengage	1 -7	North	Legacy									
30.	Learning*	Listed equity	America	Media	2.8	0%	0%						
	Total Top 30	-			357.2	40%	40%						
	Other				2.8	0%	0%						
	Total Derive	d Investments			360.0	40%	41%						

^{*} Denotes overlap with the Private Equity portfolio




Adjusted NAV per share progression

Adjusted NAV per share progression (€)

	Adjusted NAV/share at the beginning of the period	Income	Realised gains	Unrealised gains	FX	Dividend	Other	Adjusted NAV/share at end of the period	Return %	Total NAV Return %
3Q15	€1.79	€0.01	€0.00	-€0.01	-€0.01	€0.00	€0.00	€1.78	-0.4%	F 20/
4Q15	€1.78	€0.01	€0.01	€0.07	€0.02	€0.00	-€0.01	€1.88	5.6%	5.2%
1Q16	€1.88	€0.02	€0.00	€0.01	-€0.06	-€0.05	-€0.00	€1.80	-1.8%	
2Q16	€1.80	€0.02	€0.00	-€0.02	€0.03	€0.00	-€0.01	€1.82	1.2%	6.60/
3Q16	€1.82	€0.02	€0.00	€0.03	-€0.01	-€0.05	-€0.00	€1.81	2.0%	6.6%
4Q16	€1.81	€0.02	€0.00	€0.02	€0.07	€0.00	-€0.01	€1.91	5.2%	
1Q17	€1.91	€0.02	€0.00	€0.03	-€0.01	-€0.05	-€0.01	€1.89	1.4%	
2Q17	€1.89	€0.01	€0.04	€0.01	-€0.08	€0.00	-€0.02	€1.85	(2.1%)	(1.1%)
3Q17	€1.85	€0.01	€0.00	€0.03	-€0.04	-€0.05	-€0.00	€1.80	(0.3%)	


Adjusted NAV per share progression (€)





Key financial highlights at 30 September 2017

Net Asset Values per share (€/£)												
	30 Sept 2017	30 Jun 2017	31 Mar 2017	31 Dec 2016	30 Sep 2016							
NAV per share	€1.82/£1.62	€1.87/£1.64	€1.91/£1.62	€1.93/£1.65	€1.83/£1.58							
Adjusted NAV per share	€1.80/£1.58	€1.85/£1.62	€1.89/£1.60	€1.91/£1.63	€1.81/£1.57							




Total NAV split (€m)




















Portfolio composition - Private Equity


Portfolio split by sector 30 September 2017




















Portfolio composition - Derived Investments














Portfolio composition - Derived Debt Investments







Endnotes



References to "Apax Funds"

Private Equity Funds advised by Apax Partners LLP to which AGA is committed are Apax IX - consisting of a euro tranche ("AIX – EUR") and a US Dollar tranche ("AIX – USD"), AMI Opportunities Fund ("AMI"), Apax VIII ("AVIII") – consisting of a euro tranche ("AVIII – EUR") and a US Dollar tranche ("AVIIII – USD"), Apax Europe VII ("AEVII") and Apax Europe VI ("AEVII"). AGA has committed to the Apax Digital Fund ("ADF"), however ADF has yet to hold a final close. In addition, reference is made to the Apax Buyout Funds which includes AIX, AVIII, AEVII, Apax US VII, L.P. ("USVII"), AEVI and Apax Europe V ("AEV"). Please note that throughout this presentation both the funds full name and abbreviated forms are used interchangeably.

Information with Respect to AGA Performance including Gross IRRs, Net IRRs and MOICs

"Gross IRR" as used throughout this Presentation, and unless otherwise indicated, means an aggregate, annual, compound, gross internal rate of return calculated on the basis of cash receipts and payments together with the valuation of unrealised investments at the measurement date. Foreign currency cash flows have been converted at the exchange rates applicable at the date of receipt or payment by the relevant entity.

For the Company's Private Equity Investments, Gross IRR is net of fees and carried interest paid to the underlying investment manager and/or general partner of the relevant fund. For Derived Investments, Gross IRR does not reflect expenses to be borne by the relevant investment vehicle or its investors including, without limitation, performance fees, management fees, taxes and organisational, partnership or transaction expenses. "Net IRR" means Gross IRR less any expenses borne by the relevant investment vehicle or its investors including, without limitation, carried interest, management fees, taxes and organisational or transaction expenses. Please note that Multiples of Invested Capital ("MOICs) are presented in this Presentation on the basis indicated.

In certain instances, the Gross IRR shown is a concurrent IRR, meaning a gross annual IRR, calculated as if the first cash flow associated with all investments started in the same month.

